Total
0
Shares
Mesoblast (ASX:MSB) - Managing Director & CEO, Silviu Itescu - The Market Herald
Managing Director & CEO, Silviu Itescu
Source: The Australian
  • Stem cell biotech Mesoblast's (MSB) share price has jumped today after reporting positive news from its chronic heart failure phase three trial
  • The company announced in December that the main goal of its study was not met, however, a silver lining has been discovered
  • Mesoblast treated 537 patients with chronic heart failure with its stem cell treatment revascor
  • Notably, the trial has found that one single does of revascor provides a substantial and durable reduction in heart attacks, strokes and cardiac death in patients with chronic heart failure
  • Results show that the incidence of heart attacks and strokes were reduced by 60 per cent over a follow-up period of 30 months
  • Based on these results, Mesoblast intends to meet with the U.S. Food and Drug Administration (FDA) to discuss a potential approval pathway
  • On market close, Mesoblast is up 14.3 per cent and is trading at $2.56 per share

Mesoblast's (MSB) share price has jumped today after reporting positive news from its chronic heart failure phase three trial.

In December, the company announced its phase three clinical trial's primary goal was not met in regards to hospitalisation. However, the research has suggested that the drug could potentially reduce cardiovascular mortality when used in the early stages of heart failure patients.

The trial

In a twist on its past results, Mesoblast has now announced additional results from its DREAM-HF trial.

The biotech company treated 537 patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who received rexlemestrocel-L (revascor) or a control.

The trial has found that one single does of revascor provides a substantial and durable reduction in heart attacks, strokes and cardiac death in patients with chronic heart failure.

Results show that the incidence of heart attacks and strokes were reduced by 60 per cent over a follow-up period of 30 months.

Patients who received revascor had a 68 per cent reduction in the rate of recurrent hospitalisations from non-fatal heart attacks or strokes compared with controls.

What's next?

Based on these results, Mesoblast intends to meet with the U.S. Food and Drug Administration (FDA) to discuss a potential approval pathway.

Notably, heart failure affects around 6.5 million people in the U.S., and 26 million people around the globe, with increasing prevalence and incidence.

On market close, Mesoblast is up 14.3 per cent and is trading at $2.56 per share.


Subscribe


MSB by the numbers
More From The Market Herald
SUDA Pharmaceuticals (ASX:SUD) - Executive Chairman, Paul Hopper - The Market Herald

" SUDA Pharmaceuticals (ASX:SUD) shares drop as MTPS leaves ZolpiMist agreement

SUDA Pharmaceuticals (SUD) shares are down this morning after Mitsubishi Tanabe Pharma Singapore (MTPS) announced it would not proceed with its ZolpiMist agreement.
Cann Global (ASX:CGB) shares on the rise after Thailand’s hemp rules change

" Cann Global (ASX:CGB) shares on the rise after Thailand’s hemp rules change

Cann Global (CGB) shares are on the rise today after Thailand’s regulation for hemp changes.
Cellmid (ASX:CDY) - Chief Executive, Maria Halasz - The Market Herald

" Cellmid (ASX:CDY) takes first orders from Hong Kong distributor

Cellmid (CDY) has received the first order for its skincare products from Hong Kong-based distributor Ourui Health Management.
Mach7 Technologies (ASX:M7T) - CEO, Mike Lampron - The Market Herald

" Mach7 Technologies (ASX:M7T) wins $7.9M contract

Mach7 Technologies (M7T) has secured a $7.9 million contract through its wholly-owned subsidiary with U.S. nonprofit, Adventist Health System.